Boosting Exosome & Extra-Cellular Vesicle Therapies & Delivery Carriers with Optimal Characterization, Improved Tropism & GMP-Grade Production For Regenerative & Precision Medicine
The exosome and extracellular vesicle (EV) fields moved closer to groundbreaking clinical and commercial breakthroughs in 2025, with major therapeutic advancements showcased by leading biopharma companies including Rion, Direct Biologics, Aegle Therapeutics, Aruna Bio, EXO Biologics, and more.
Highlighting the industry's progress throughout the year, the 7th Exosome-Based Therapeutics Development Summit returned to Boston with never-before-seen data, covering the full pipeline from discovery to optimized characterization, scalable manufacturing, and clinical outcomes. As the only industry-dedicated summit focused on bridging science and business, it played a pivotal role in advancing effective regenerative and precision medicines.
More than 80 key experts across exosome biology, Exosome Biology, R&D, CMC to Business Development came together for an unparalleled opportunity to exchange insights, foster partnerships, and map out the therapeutic efficacy and delivery potential of exosomes and EVs on the path to commercialization and patient impact.
Attending Companies Include